business

Guggenheim reiterates Abivax stock rating on cancer data

Investing.com · Jun 30, 2026, 11:44 AM · Also reported by 4 other sources

Read full story on Investing.com → More top stories

Also covered by

Yahoo Finance Is BeOne Medicines AG (ONC) Stock Positioned for Growth After Encouraging ASCO Cancer Data? Yahoo Finance Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data? Yahoo Finance Is Amylyx Pharmaceuticals, Inc. (AMLX) Stock Ready for a Breakout Ahead of Key LUCIDITY Trial Data? Euronews Abivax shares jump 36% as new trial data support ulcerative colitis drug obefazimod

Aggregated and edited by the Scoop newsroom. We surface news from Investing.com alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

Guggenheim reiterates Abivax stock rating on cancer data

Also covered by

More in business